SHStephan V. Hendriks

Stephan V. Hendriks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephan V. Hendriks has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Menno V. Huisman

    Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands

    7 shared publications
  • Antonio Iglesias del Sol

    Department of Internal Medicine, Alrijne Hospital, Leiderdorp, The Netherlands

    5 shared publications
  • Frederikus A. Klok

    Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands

    5 shared publications
  • Laura M. Faber

    Department of Internal Medicine, Rode Kruis Hospital, Beverwijk, The Netherlands

    5 shared publications
  • Michiel Eijsvogel

    Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, the Netherlands

    5 shared publications
  • Albert T. A. Mairuhu

    Department of Internal Medicine, Haga Teaching Hospital, The Hague, the Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism

    by Cindy Mm de Jong, Marc Blondon, Cihan Ay, Andrea Buchmüller, Jan Beyer-Westendorf, Judith Biechele, Laurent Bertoletti, Giovanna Colombo, Marco Paolo Donadini, Stephan V Hendriks, et al.

    Preliminary data and clinical experience have suggested an increased risk of abnormal uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid data are lacking. The TEAM-VTE study was an international multicenter prospective cohort study in women aged 18 to 50 years diagnosed with acute venous thromboembolism (VTE). Menstrual blood loss was measured by pictorial blood loss assessment charts at baseline for the last menstrual cycle before VTE diagnosis and prospectively for each cycle during 3 to 6 months of follow-up. AUB was defined as an increased score on the pictorial blood loss assessment chart (>100 or >150) or self-reported AUB. AUB-related quality of life (QoL) was assessed at baseline and the end of follow-up using the Menstrual Bleeding Questionnaire. The study was terminated early because of slow recruitment attributable to the COVID-19 pandemic. Of the 98 women, 65 (66%) met at least one of the 3 definitions of AUB during follow-up (95% confidence interval [CI], 57%-75%). AUB occurred in 60% of women (36 of 60) without AUB before VTE diagnosis (new-onset AUB; 95% CI, 47%-71%). Overall, QoL decreased over time, with a mean Menstrual Bleeding Questionnaire score increase of 5.1 points (95% CI, 2.2-7.9), but this decrease in QoL was observed only among women with new-onset AUB. To conclude, 2 of every 3 women who start anticoagulation for acute VTE experience AUB, with a considerable negative impact on QoL. These findings should be a call to action to increase awareness and provide evidence-based strategies to prevent and treat AUB in this setting. This was an academic study registered at www.clinicaltrials.gov as #NCT04748393; no funding was received.


  • Top Cited Papers
    Open Access

    Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial

    by Pierre-Marie Roy, Andrea Penaloza, Olivier Hugli, Frederikus A Klok, Armelle Arnoux, Antoine Elias, Francis Couturaud, Luc-Marie Joly, Raphaëlle Lopez, Laura M Faber, et al.

    The aim of this study is to compare the Hestia rule vs. the simplified Pulmonary Embolism Severity Index (sPESI) for triaging patients with acute pulmonary embolism (PE) for home treatment. Normotensive patients with PE of 26 hospitals from France, Belgium, the Netherlands, and Switzerland were randomized to either triaging with Hestia or sPESI. They were designated for home treatment if the triaging tool was negative and if the physician-in-charge, taking into account the patient’s opinion, did not consider that hospitalization was required. The main outcomes were the 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death (non-inferiority analysis with 2.5% absolute risk difference as margin), and the rate of patients discharged home within 24 h after randomization (NCT02811237). From January 2017 through July 2019, 1975 patients were included. In the per-protocol population, the primary outcome occurred in 3.82% (34/891) in the Hestia arm and 3.57% (32/896) in the sPESI arm (P = 0.004 for non-inferiority). In the intention-to-treat population, 38.4% of the Hestia patients (378/984) were treated at home vs. 36.6% (361/986) of the sPESI patients (P = 0.41 for superiority), with a 30-day composite outcome rate of 1.33% (5/375) and 1.11% (4/359), respectively. No recurrent or fatal PE occurred in either home treatment arm. For triaging PE patients, the strategy based on the Hestia rule and the strategy based on sPESI had similar safety and effectiveness. With either tool complemented by the overruling of the physician-in-charge, more than a third of patients were treated at home with a low incidence of complications. The international randomized HOME-PE study demonstrates that, for triaging patients with acute pulmonary embolism for home treatment, the Hestia rule and the simplified Pulmonary Embolism Severity Index, complemented by the physician's overruling, are equally safe and efficient.


  • Home Treatment Compared to Initial Hospitalization in Normotensive Patients with Acute Pulmonary Embolism in the Netherlands: A Cost Analysis

    by Stephan V. Hendriks, Wilbert B. van Den Hout, Thomas van Bemmel, Ingrid M. Bistervels, Michiel Eijsvogel, Laura M. Faber, Herman M. A. Hofstee, Tom van der Hulle, Antonio Iglesias del Sol, Marieke J. H. A. Kruip, et al.

    Background Venous thromboembolism constitutes substantial health care costs amounting to approximately 60 million euros per year in the Netherlands. Compared with initial hospitalization, home treatment of pulmonary embolism (PE) is associated with a cost reduction. An accurate estimation of cost savings per patient treated at home is currently lacking. Aim The aim of this study was to compare health care utilization and costs during the first 3 months after a PE diagnosis in patients who are treated at home versus those who are initially hospitalized. Methods Patient-level data of the YEARS cohort study, including 383 normotensive patients diagnosed with PE, were used to estimate the proportion of patients treated at home, mean hospitalization duration in those who were hospitalized, and rates of PE-related readmissions and complications. To correct for baseline differences within the two groups, regression analyses was performed. The primary outcome was the average total health care costs during a 3-month follow-up period for patients initially treated at home or in hospital. Results Mean hospitalization duration for the initial treatment was 0.69 days for those treated initially at home (n = 181) and 4.3 days for those initially treated in hospital (n = 202). Total average costs per hospitalized patient were €3,209 and €1,512 per patient treated at home. The adjusted mean difference was €1,483 (95% confidence interval: €1,181–1,784). Conclusion Home treatment of hemodynamically stable patients with acute PE was associated with an estimated net cost reduction of €1,483 per patient. This difference underlines the advantage of triage-based home treatment of these patients.


  • Open Access

    The prognostic value of ECG-derived ventricular gradient in early adverse events in acute pulmonary embolism patients

    by F.M.M. Meijer, S.V. Hendriks, M.V. Huisman, C.A. Swenne, P. Kies, M.R.M. Jongbloed, A.D. Egorova, H.W. Vliegen, F.A. Klok


  • Open Access

    Current practice patterns of outpatient management of acute pulmonary embolism: A post-hoc analysis of the YEARS study

    by Stephan V. Hendriks, Roisin Bavalia, Thomas van Bemmel, Ingrid M. Bistervels, Michiel Eijsvogel, Laura M. Faber, Jaap Fogteloo, Herman M.A. Hofstee, Tom van der Hulle, Antonio Iglesias del Sol, et al.


  • Right Ventricle–to–Left Ventricle Diameter Ratio Measurement Seems to Have No Role in Low-Risk Patients with Pulmonary Embolism Treated at Home Triaged by Hestia Criteria

    by Stephan V. Hendriks, Frederikus A Klok, Paul L. Den Exter, Michiel Eijsvogel, Laura M. Faber, Herman M. A. Hofstee, Antonio Iglesias del Sol, Lucia J. M. Kroft, Albert T. A. Mairuhu, Menno V. Huisman, et al.


  • Reasons for Hospitalization of Patients with Acute Pulmonary Embolism Based on the Hestia Decision Rule

    by Stephan V. Hendriks, Paul L. Den Exter, Wendy Zondag, Rolf Brouwer, Michiel Eijsvogel, Marco J. Grootenboers, Laura M. Faber, Roxanne Heller-Baan, Herman M. A. Hofstee, Antonio Iglesias del Sol, et al.

    Background The Hestia criteria can be used to select pulmonary embolism (PE) patients for outpatient treatment. The subjective Hestia criterion “medical/social reason for admission” allows the treating physician to consider any patient-specific circumstances in the final management decision. It is unknown how often and why this criterion is scored. Methods This is a patient-level post hoc analysis of the combined Hestia and Vesta studies. The main outcomes were the frequency of all scored Hestia items in hospitalized patients and the explicit reason for scoring the subjective criterion. Hemodynamic parameters and computed tomography-assessed right ventricular (RV)/left ventricular (LV) ratio of those only awarded with the subjective criterion were compared with patients treated at home. Results From the 1,166 patients screened, data were available for all 600 who were hospitalized. Most were hospitalized to receive oxygen therapy (45%); 227 (38%) were only awarded with the subjective criterion, of whom 51 because of “intermediate to intermediate-high risk PE.” Compared with patients with intermediate risk PE (RV/LV ratio > 1.0) treated at home (179/566, 32%), hospitalized patients with only the subjective criterion had a higher mean RV/LV ratio (mean difference +0.30, 95% confidence interval [CI] 0.19–0.41) and a higher heart rate (+18/min, 95% CI 10–25). No relevant differences were observed for other hemodynamic parameters. Conclusion The most frequent reason for hospital admission was oxygen therapy. In the decision to award the subjective criterion as sole argument for admission, the severity of the RV overload and resulting hemodynamic response of the patient was taken into account rather than just abnormal RV/LV ratio.


  • Open Access

    Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice

    by Stephan V. Hendriks, Frederikus A. Klok, Wilhelmina J.E. Stenger, Albert T.A. Mairuhu, Jeroen Eikenboom, Jaap Fogteloo, Menno V. Huisman

    Introduction Phase 3 trials have shown comparable efficacy of direct oral anticoagulants (DOACs) and vitamin K antagonists in patients with acute venous thromboembolism (VTE), with less major bleeding events in patients randomized to DOAC treatment. With DOACs being increasingly used in clinical practice, evaluation of the DOACs in daily practice-based conditions is needed to confirm their safety and effectiveness. The aim of this study is to evaluate the effectiveness and safety of apixaban in VTE patients in daily practice. Methods In this retrospective cohort study, consecutive patients diagnosed with VTE in two Dutch hospitals (Leiden University Medical Center, Leiden and Haga Teaching Hospital, The Hague) were identified based on administrative codes. We assessed recurrent VTE, major bleeding and mortality during a 3-month follow-up period in those treated with apixaban. Results Of 671 consecutive VTE patients treated with apixaban, 371 presented with acute pulmonary embolism (PE) and 300 patients with deep-vein thrombosis. During 3 months treatment, 2 patients had a recurrent VTE (0.3%; 95% confidence interval [CI]: 0.08–1.1), 12 patients had major bleeding (1.8%; 95% CI: 1.0–3.2), and 11 patients died (1.6%; 95% CI: 0.9–2.9), of which one patient with recurrent PE and one because of a intracerebral bleeding. Conclusion In this daily practice-based cohort, apixaban yielded a low incidence of recurrent VTE, comparable to the phase 3 AMPLIFY study patients. The incidence of major bleeding was higher than in the AMPLIFY-study patients, reflecting the importance of daily practice evaluation and the fact that results from phase III clinical studies cannot be directly extrapolated toward daily practice.


  • Open Access

    Uncertain Value of High‐sensitive Troponin T for Selecting Patients With Acute Pulmonary Embolism for Outpatient Treatment by Hestia Criteria

    by Stephan V. Hendriks, Mareike Lankeit, Paul L. Den Exter, Wendy Zondag, Rolf Brouwer, Michiel Eijsvogel, Marco J. Grootenboers, Laura M. Faber, Roxanne Heller‐Baan, Herman M. A. Hofstee, et al.


  • Open Access

    Home treatment of patients with cancer-associated venous thromboembolism – An evaluation of daily practice

    by Stephan V. Hendriks, Menno V. Huisman, Jeroen C.J. Eikenboom, Jaap Fogteloo, Hans Gelderblom, Felix J.M. van der Meer, Wilhelmina J.E. Stenger, Arie J. Verschoor, Henri H. Versteeg, Frederikus A. Klok